CLOs on the Move


 
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology. In addition to HD-MAP HexaPro clinical studies of a COVID-19 vaccine patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions. Vaxxas core technology was initially developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vaxxas.com
  • 47 Thorndike Street Suite B1-1
    Cambridge, MA USA 02141
  • Phone: n/a

Executives

Name Title Contact Details
Dan Devine
General Counsel Profile

Similar Companies

Cannalysis Labs

Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.

Armune

Armune BioScience, Inc. develops and commercializes molecular diagnostic and prognostic tests for prostate, lung, and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. The company’s corporate headquarters are in Kalamazoo, MI and the laboratory is in Ann Arbor, MI.

20/20 GeneSystems Inc

20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Organization of EPA and DHA Omega-3s

We were founded in 2006 as GO3ETA, Inc., but do business as the Global Organization for EPA and DHA Omega-3s (GOED).  The roots of GOED go back to 2000 when the industry collaborated to petition the US Food and Drug Administration to establish a heart disease risk reduction claim for omega-3s.  The companies involved later formalized the relationship by forming the Omega-3 Working Group at the Council for Responsible Nutrition and collaborating again to develop what is now known as the GOED Voluntary Monograph. In 2006, when the Working Group was dissolved, twelve of the companies banded together to found GOED with a strong mandate to grow our membership to represent all sections of the EPA and DHA market.